New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD
Scott Solomon, MD
Mikhail Kosiborod, MD
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Erin Michos
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
CETP inhibition: Lessons from two decades of clinical trials
Understanding the etiology of HCM and pathways for intervention
Roberto Barriales-Villa, MD, PhD
The clinical challenge of managing a patient with HCM
Iacopo Olivotto, MD
What are the challenges in making the right diagnosis in HCM?
Perry Elliott, MD
Updates From the 7th World Symposium Task Force
Eric D. Austin, MD, MSCI
Hilary M. DuBrock, MD
H. James Ford, MD
Gustavo A. Heresi, MD, MS
Gergely Meszaros, JD, MSc
Oksana A. Shlobin, MD
Ioana Preston, MD
Lucilla Piccari, MD, PhD
Managing hypertrophic cardiomyopathy in clinical practice: The patient journey
Comprehensive Management of Individuals with CKM Syndrome
Muthiah Vaduganathan, MD
Optimizing Care for Patients with CKM Syndrome: A Multidisciplinary Approach
Jürgen Floege, MD
Muthiah Vaduganathan, MD, MPH
Definition and Staging of CKM Syndrome
Case-Based Learning and Future Directions
Jurgen Floege MD
Screening for CKM Syndrome
Nonsteroidal MRAs: The CKD/T1D Potential
John McMurray, MD
Hiddo L. Heerspink, PhD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.